Cellectis S.A. (NASDAQ:CLLS) Position Boosted by Eqis Capital Management Inc.
Eqis Capital Management Inc. boosted its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 27.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,687 shares of the biotechnology company’s stock after buying an additional 2,287 shares during the period. Eqis Capital Management Inc.’s holdings in Cellectis were worth $276,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sphera Funds Management LTD. bought a new position in Cellectis during the first quarter worth about $3,832,000. Vident Investment Advisory LLC raised its position in Cellectis by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock worth $1,224,000 after buying an additional 8,496 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in Cellectis during the first quarter worth about $214,000. Institutional investors and hedge funds own 16.08% of the company’s stock.
Shares of Cellectis S.A. (NASDAQ CLLS) traded down 0.21% on Monday, reaching $23.21. The company’s stock had a trading volume of 53,437 shares. Cellectis S.A. has a 52 week low of $16.09 and a 52 week high of $28.77. The stock has a 50-day moving average of $25.17 and a 200 day moving average of $23.25. The stock’s market capitalization is $820.13 million.
TRADEMARK VIOLATION NOTICE: “Cellectis S.A. (NASDAQ:CLLS) Position Boosted by Eqis Capital Management Inc.” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/07/eqis-capital-management-inc-purchases-2287-shares-of-cellectis-s-a-nasdaqclls-updated.html.
CLLS has been the subject of a number of analyst reports. Jefferies Group LLC restated a “buy” rating and set a $47.00 price objective on shares of Cellectis in a research report on Wednesday, April 26th. Oppenheimer Holdings, Inc. set a $40.00 price objective on Cellectis and gave the company a “buy” rating in a research report on Wednesday, May 10th. Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a research report on Wednesday, July 19th. Finally, BidaskClub lowered Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $41.80.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Stock Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related stocks with our FREE daily email newsletter.